348 related articles for article (PubMed ID: 16199247)
1. A retrospective Evaluation of fluconazole for the treatment of Candida glabrata fungemia.
Wilson AG; Micek ST; Ritchie DJ
Clin Ther; 2005 Aug; 27(8):1228-37. PubMed ID: 16199247
[TBL] [Abstract][Full Text] [Related]
2. Fungaemia caused by Candida glabrata with reduced susceptibility to fluconazole due to altered gene expression: risk factors, antifungal treatment and outcome.
Tumbarello M; Sanguinetti M; Trecarichi EM; La Sorda M; Rossi M; de Carolis E; de Gaetano Donati K; Fadda G; Cauda R; Posteraro B
J Antimicrob Chemother; 2008 Dec; 62(6):1379-85. PubMed ID: 18782778
[TBL] [Abstract][Full Text] [Related]
3. Early prediction of Candida glabrata fungemia in nonneutropenic critically ill patients.
Cohen Y; Karoubi P; Adrie C; Gauzit R; Marsepoil T; Zarka D; Clec'h C
Crit Care Med; 2010 Mar; 38(3):826-30. PubMed ID: 20042858
[TBL] [Abstract][Full Text] [Related]
4. Initial treatment and outcome of Candida glabrata versus Candida albicans bloodstream infection.
Klevay MJ; Horn DL; Neofytos D; Pfaller MA; Diekema DJ;
Diagn Microbiol Infect Dis; 2009 Jun; 64(2):152-7. PubMed ID: 19376667
[TBL] [Abstract][Full Text] [Related]
5. Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome.
Safdar A; van Rhee F; Henslee-Downey JP; Singhal S; Mehta J
Bone Marrow Transplant; 2001 Nov; 28(9):873-8. PubMed ID: 11781648
[TBL] [Abstract][Full Text] [Related]
6. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study.
Garey KW; Rege M; Pai MP; Mingo DE; Suda KJ; Turpin RS; Bearden DT
Clin Infect Dis; 2006 Jul; 43(1):25-31. PubMed ID: 16758414
[TBL] [Abstract][Full Text] [Related]
7. Candida glabrata fungemia: experience in a tertiary care center.
Malani A; Hmoud J; Chiu L; Carver PL; Bielaczyc A; Kauffman CA
Clin Infect Dis; 2005 Oct; 41(7):975-81. PubMed ID: 16142662
[TBL] [Abstract][Full Text] [Related]
8. Therapy and outcome of Candida glabrata versus Candida albicans bloodstream infection.
Klevay MJ; Ernst EJ; Hollanbaugh JL; Miller JG; Pfaller MA; Diekema DJ
Diagn Microbiol Infect Dis; 2008 Mar; 60(3):273-7. PubMed ID: 18024053
[TBL] [Abstract][Full Text] [Related]
9. The epidemiology of Candida colonization and invasive candidiasis in a surgical intensive care unit where fluconazole prophylaxis is utilized: follow-up to a randomized clinical trial.
Magill SS; Swoboda SM; Shields CE; Colantuoni EA; Fothergill AW; Merz WG; Lipsett PA; Hendrix CW
Ann Surg; 2009 Apr; 249(4):657-65. PubMed ID: 19300221
[TBL] [Abstract][Full Text] [Related]
10. Candida glabrata fungaemia in a tertiary centre in Taiwan: antifungal susceptibility and outcomes.
Ruan SY; Huang YT; Chu CC; Yu CJ; Hsueh PR
Int J Antimicrob Agents; 2009 Sep; 34(3):236-9. PubMed ID: 19361960
[TBL] [Abstract][Full Text] [Related]
11. [Current treatment of candidemia in non-neutropenic patients. Amphotericin B or fluconazole? A retrospective study of 62 consecutive patients].
Cobo Reinoso P; Aguado García JM; Lumbreras Bermejo C; Pérez Vela JL; Caballero Cubedo R; Sanz Sanz F; Noriega Rodríguez AR
Rev Clin Esp; 1997 Dec; 197(12):799-803. PubMed ID: 9477669
[TBL] [Abstract][Full Text] [Related]
12. Candida glabrata fungaemia in intensive care units.
Ruan SY; Lee LN; Jerng JS; Yu CJ; Hsueh PR
Clin Microbiol Infect; 2008 Feb; 14(2):136-40. PubMed ID: 18042196
[TBL] [Abstract][Full Text] [Related]
13. The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy.
Hachem R; Hanna H; Kontoyiannis D; Jiang Y; Raad I
Cancer; 2008 Jun; 112(11):2493-9. PubMed ID: 18412153
[TBL] [Abstract][Full Text] [Related]
14. Do clinical features allow for accurate prediction of fungal pathogenesis in bloodstream infections? Potential implications of the increasing prevalence of non-albicans candidemia.
Shorr AF; Lazarus DR; Sherner JH; Jackson WL; Morrel M; Fraser VJ; Kollef MH
Crit Care Med; 2007 Apr; 35(4):1077-83. PubMed ID: 17312565
[TBL] [Abstract][Full Text] [Related]
15. [Epidemiological study of invasive nosocomial candidiasis in 2 teaching hospitals in Beijing].
Cao B; Wang H; Wu L; Sun WJ; Li F; Liu YM
Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(28):1970-3. PubMed ID: 19062737
[TBL] [Abstract][Full Text] [Related]
16. Survival in Patients with Candida glabrata Bloodstream Infection Is Associated with Fluconazole Dose.
Eschenauer GA; Carver PL; Patel TS; Lin SW; Klinker KP; Pai MP; Lam SW
Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29581112
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of Candida glabrata and its response to boric acid vaginal suppositories in comparison with oral fluconazole in patients with diabetes and vulvovaginal candidiasis.
Ray D; Goswami R; Banerjee U; Dadhwal V; Goswami D; Mandal P; Sreenivas V; Kochupillai N
Diabetes Care; 2007 Feb; 30(2):312-7. PubMed ID: 17259500
[TBL] [Abstract][Full Text] [Related]
18. Candida glabrata fungemia cured by antibiotic-lock therapy: case report and short review.
Angel-Moreno A; Boronat M; Bolaños M; Carrillo A; González S; Pérez Arellano JL
J Infect; 2005 Oct; 51(3):e85-7. PubMed ID: 16230210
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study.
Nguyen MH; Peacock JE; Tanner DC; Morris AJ; Nguyen ML; Snydman DR; Wagener MM; Yu VL
Arch Intern Med; 1995 Dec 11-25; 155(22):2429-35. PubMed ID: 7503601
[TBL] [Abstract][Full Text] [Related]
20. Activities of fluconazole and voriconazole against bloodstream isolates of Candida glabrata and Candida krusei: a 14-year study in a Spanish tertiary medical centre.
Quindós G; Sánchez-Vargas LO; Villar-Vidal M; Eraso E; Alkorta M; Hernández-Almaraz JL
Int J Antimicrob Agents; 2008 Mar; 31(3):266-71. PubMed ID: 18054468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
